REC-2282

Recursion has initiated the EXCELERIZE Phase 1 clinical trial of REC-3565, a selective MALT1 inhibitor designed to treat relapsed or refractory B-cell lymphomas.

Recursion Pharmaceuticals and Exscientia have completed a landmark $700 million merger, marking the largest AI-focused life sciences deal to date and combining complementary capabilities in biological and chemical AI platforms.

Arvinas plans to initiate two Phase 3 trials in 2025 for vepdegestrant in ER+/HER2- metastatic breast cancer, one in the first-line setting with atirmociclib and another in the second-line setting with a CDK4/6 inhibitor.

Recursion Pharmaceuticals anticipates seven clinical trial readouts within approximately 18 months, spanning multiple therapeutic areas and clinical phases.

Recursion expects to release Phase 2 data for REC-994 in Cerebral Cavernous Malformation in Q3 2024, with the SYCAMORE trial fully enrolled.